Menu
Not yet recruiting NCT07093775

Additional Prognostic Value of Tumor Grade Beyond the 21-gene Recurrence Score

— Observational Breast Cancer Tumor Grade

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: Tumor grade (I or II vs. III).
Who it may be relevant to
Registry conditions: Breast Cancer, Tumor Grade. Basic parameters: from 20 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
Center list to be confirmed — check the primary protocol.
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Unsure about the terms? Read our patient guide →

Official title

Prognostic Implication of Tumor Grade in Patients With Node-negative Breast Cancer Aged ≤ 50 Years With 21-gene Recurrence Scores of 11-25

Overview

To evaluated the prognostic significance of tumor grade in patients with node-negative, hormone receptor-positive, and human epidermal growth factor receptor 2-negative breast cancers treated according to RS-guided strategies.

Interventions

  • Other Tumor grade (I or II vs. III)
    We compared the prognosis according to the tumor grade stratified by 21-gene recurrence score

Primary outcome measures

  • Recurrence-free interval [Time frame: through study completion, an average of 5 year]

Eligibility criteria

Inclusion criteria

  • Patients with hormone receptor-positive, HER2-negative early-stage breast cancer
  • Patients treated between January 2011 and December 2023
  • Patients with available clinicopathologic data and 21-gene Oncotype DX assay results confirmed through electronic medical records

Exclusion criteria

  • Patients with breast cancer under the age of 20
  • Patients diagnosed with stage IV breast cancer
  • Patients for whom clinicopathologic data cannot be retrieved from electronic medical records

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Observational model
Cohort

Study locations

Center list to be confirmed — check the primary protocol.

Identifiers

NCT: NCT07093775 · 3-2025-0107

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗